This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2014 Mar;50(5):1040-1.

doi: 10.1016/j.ejca.2013.12.017. Epub 2014 Jan 22.

Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate-resistant prostate cancer

David Thomson¹, Natalie Charnley², Omi Parikh²

Affiliations

Affiliations

¹ Department of Clinical Oncology, Rosemere Cancer Centre, Royal Preston Hospital, UK. Electronic address: davidthomson@doctors.org.uk.
² Department of Clinical Oncology, Rosemere Cancer Centre, Royal Preston Hospital, UK.

PMID: 24462374
DOI: 10.1016/j.ejca.2013.12.017

Comment

Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate-resistant prostate cancer

David Thomson et al. Eur J Cancer. 2014 Mar.

. 2014 Mar;50(5):1040-1.

doi: 10.1016/j.ejca.2013.12.017. Epub 2014 Jan 22.

Authors

David Thomson¹, Natalie Charnley², Omi Parikh²

Affiliations

¹ Department of Clinical Oncology, Rosemere Cancer Centre, Royal Preston Hospital, UK. Electronic address: davidthomson@doctors.org.uk.
² Department of Clinical Oncology, Rosemere Cancer Centre, Royal Preston Hospital, UK.

PMID: 24462374
DOI: 10.1016/j.ejca.2013.12.017

No abstract available

PubMed Disclaimer

Comment in

Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer.
Lorente D, Bianchini D, Rodriguez-Vida A, Omlin A, Pezaro C, Ferraldeschi R, Zivi A, Attard G, Chowdhury S, De Bono JS. Lorente D, et al. Eur J Cancer. 2014 Mar;50(5):1042-3. doi: 10.1016/j.ejca.2013.12.016. Epub 2014 Jan 13. Eur J Cancer. 2014. PMID: 24433842 No abstract available.

Comment on

Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.
Bianchini D, Lorente D, Rodriguez-Vida A, Omlin A, Pezaro C, Ferraldeschi R, Zivi A, Attard G, Chowdhury S, de Bono JS. Bianchini D, et al. Eur J Cancer. 2014 Jan;50(1):78-84. doi: 10.1016/j.ejca.2013.08.020. Epub 2013 Sep 25. Eur J Cancer. 2014. PMID: 24074764

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations